2-(tert-Butyl)thiazole-4-carboxamide | 848555-16-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(tert-Butyl)thiazole-4-carboxamide
• 英文别名: 2-tert-butyl-1,3-thiazole-4-carboxamide
• CAS: 848555-16-8
• 化学式: C₈H₁₂N₂OS
• mdl: MFCD20545910
• 分子量: 184.262
• InChiKey: XDGSHTNLCHSQFU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  84.2
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Regents of the University of Minnesota

  公开号：US20200339555A1

  公开（公告）日：2020-10-29

  The invention provides a compound of formula I: or a salt thereof, wherein R 1 , R 2 , R 3 , A and n have any of the values described in the specification, as well as compositions comprising a compound of formula I, and methods of preparing and use thereof. The compounds are useful as vaccine adjuvant potentiators.

  该发明提供了化合物I的化学式，或其盐，其中R1、R2、R3、A和n具有规范中描述的任何值，以及包含化合物I的组合物，以及其制备和使用方法。这些化合物可用作疫苗佐剂增强剂。
• [EN] HETEROARYLMETHYL AMIDES<br/>[FR] HÉTÉROARYLMÉTHYL-AMIDES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2012032018A1

  公开（公告）日：2012-03-15

  The present invention relates to compounds of the formula I wherein A1, A2, A3 and R1 to R8 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis and cardiovascular diseases.

  本发明涉及公式I中的化合物，其中A1、A2、A3和R1至R8在描述中有定义，以及其药用盐，其制备方法，含有它们的药物组合物以及它们作为药物用于治疗和/或预防可以用HDL-胆固醇升高剂治疗的疾病，如特别是脂质代谢异常、动脉粥样硬化和心血管疾病。
• HETEROARYLMETHYL AMIDES
  申请人：Hoffmann-La Roche Inc.

  公开号：US20140194436A1

  公开（公告）日：2014-07-10

  The present invention relates to compounds of the formula wherein A 1 , A 2 , A 3 and R 1 to R 8 are defined in the description, and to pharmaceutically acceptable salts thereof, their manufacture, pharmaceutical compositions containing them and their use as medicaments for the treatment and/or prophylaxis of diseases which can be treated with HDL-cholesterol raising agents, such as particularly dyslipidemia, atherosclerosis and cardiovascular diseases.

  本发明涉及以下式子的化合物，其中A1，A2，A3和R1至R8在说明书中有定义，以及其药学上可接受的盐，它们的制造，含有它们的制药组合物以及它们作为药物治疗和/或预防可以用高密度脂蛋白胆固醇升高剂治疗的疾病，例如特别是失调脂质血症，动脉硬化和心血管疾病。
• Novel Nucleoside Derivatives
  申请人：Reddy K. Raja

  公开号：US20090131370A1

  公开（公告）日：2009-05-21

  Compounds of Formulae I-XVI, stereoisomers, and pharmaceutically acceptable salts or prodrugs thereof, their preparation, and their uses for the treatment of viral diseases including hepatitis C viral infection, cancer, diabetes, and other diseases are described: formula (I).
• BISHETEROCYCLIC CARBONYL SUBSTITUTED DIHYDROPYRAZOLE COMPOUND, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
  申请人：GENFLEET THERAPEUTICS (SHANGHAI) INC.

  公开号：US20220235032A1

  公开（公告）日：2022-07-28

  A substituted dihydropyrazole compound as shown in formula I, which compound has a selective inhibitory effect on RIPK1, and a pharmaceutically acceptable salt, a stereoisomer, a solvate or a prodrug thereof, wherein the definition of each group in the formula is detailed in the description. In addition is a pharmaceutical composition containing the compound, and the use thereof in the preparation of a drug for treating RIPK1-related diseases or conditions.